Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 18;9(6):858-62.
doi: 10.18240/ijo.2016.06.12. eCollection 2016.

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion

Affiliations

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion

Kaveh Abri Aghdam et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the association between the size of peripheral retinal non-perfusion and the number of intravitreal ranibizumab injections in patients with treatment-naive branch retinal vein occlusion (BRVO) and macular edema.

Methods: A total of 53 patients with treatment-naive BRVO and macular edema were included. Each patient underwent a full ophthalmologic examination including optical coherence tomography (OCT) imaging and ultra wide-field fluorescein angiography (UWFA). Monthly intravitreal ranibizumab injections were applied according to the recommendations of the German Ophthalmological Society. Two independent, masked graders quantified the areas of peripheral retinal non-perfusion.

Results: Intravitreal injections improved best-corrected visual acuity (BCVA) significantly from 22.23±16.33 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters to 36.23±15.19 letters (P<0.001), and mean central subfield thickness significantly reduced from 387±115 µm to 321±115 µm (P=0.01). Mean number of intravitreal ranibizumab injections was 3.61±1.56. The size of retinal non-perfusion correlated significantly with the number of intravitreal ranibizumab injections (R=0.724, P<0.001).

Conclusion: Peripheral retinal non-perfusion in patients with BRVO associates significantly with intravitreal ranibizumab injections in patients with BRVO and macular edema.

Keywords: angiography; branch retinal vein occlusion; non-perfusion; retina; wide-field.

PubMed Disclaimer

Figures

Figure 1
Figure 1. En face wide-field fundus image of the right eye with BRVO.
Figure 2
Figure 2. Optos fluorescein angiogram of the same patient at arterio-venous (A) and late venous (B) phases
The late phase image reveals central fluorescein leakage inferior to the fovea and extensive areas of non-perfusion in the infero-temporal part of the peripheral fundus.
Figure 3
Figure 3. Quantification of the amount of non-perfused areas using the grid with 27×17 square fields approximately the size of the optic disc.

Similar articles

Cited by

References

    1. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24(4):493–519. - PubMed
    1. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56(4):281–299. - PubMed
    1. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094–1101.e5. - PubMed
    1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513–518. - PubMed
    1. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, Cushman M, Wong TY. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 2008;49(10):4297–4302. - PMC - PubMed

LinkOut - more resources